BRIEF—Lilly partners with Atomwise for AI-driven development

Atomwise has agreed a multi-year deal with Eli Lilly to apply the firm’s AI technology, starting with up to ten drug targets selected by Lilly, with the goal of accelerating identification and development.

Chief executive Abraham Heifets said: “Lilly has made it clear that they are focused on developing drugs for novel target proteins, which are often challenging and less well studied.”

The firm could receive up to $1 million per target in discovery milestones and over half a billion dollars in potential development and commercialization milestones in total.